The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 May 2014 11:49

RNS Number : 1157I
Bank of America Merrill Lynch
27 May 2014
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date dealing undertaken:

23/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB0009895292

Purchase

855,516

43.28 GBP

42.17 GBP

Common - ISIN GB0009895292

Purchase

252,253

484.2 SEK

472.3 SEK

Common - ISIN GB0009895292

Sale

836,886

43.28 GBP

42.26 GBP

Common - ISIN GB0009895292

Sale

248,808

481.6 SEK

473.81 SEK

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB0009895292

Swaps

Long

2

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

20

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

68

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

551

42.471 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

1

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

9

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

11

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

57

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

7

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

13

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

1,500

42.354 GBP

Common - ISIN GB0009895292

Swaps

Long

36,585

43.077 GBP

Common - ISIN GB0009895292

Swaps

Short

36,585

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

58,840

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

85,863

42.434 GBP

Common - ISIN GB0009895292

Swaps

Long

62,717

43.12 GBP

Common - ISIN GB0009895292

Swaps

Long

100,000

43.192 GBP

Common - ISIN GB0009895292

Swaps

Short

1,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

426

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

1,277

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

136

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

33

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

103

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

4,034

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

1,009

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

3,025

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

600

42.371 GBP

Common - ISIN GB0009895292

Swaps

Long

600

43.091 GBP

Common - ISIN GB0009895292

Swaps

Short

13,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

3,423

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

10,280

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

2,500

42.466 GBP

Common - ISIN GB0009895292

Swaps

Long

2,266

43.28 GBP

Common - ISIN GB0009895292

Swaps

Long

143

43.083 GBP

Common - ISIN GB0009895292

Swaps

Short

96

43.283 GBP

Common - ISIN GB0009895292

Swaps

Short

82,500

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

150,000

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

179

43.286 GBP

Common - ISIN GB0009895292

Swaps

Short

104

43.283 GBP

Common - ISIN GB0009895292

Swaps

Long

164,325

42.94 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

20,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

600

481.328 SEK

Common - ISIN GB0009895292

Swaps

Short

600

474.471 SEK

Common - ISIN GB0009895292

Swaps

Short

68,815

42.563 GBP

Common - ISIN GB0009895292

Swaps

Long

68,815

42.576 GBP

Common - ISIN GB0009895292

Swaps

Long

1,561

42.576 GBP

Common - ISIN GB0009895292

Swaps

Short

1,000

42.318 GBP

Common - ISIN GB0009895292

Swaps

Long

1,000

42.076 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

27/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDURSDBGSR
Date   Source Headline
2nd May 20247:00 amRNSCalquence combination improved PFS in 1L MCL
1st May 20243:00 pmRNSTotal Voting Rights
29th Apr 20247:05 amRNSTruqap recommended for EU breast cancer approval
29th Apr 20247:00 amRNSEnhertu improved PFS in HER2-low and ultralow
25th Apr 20247:00 amRNS1st Quarter Results
11th Apr 20245:30 pmRNSResult of AGM
11th Apr 20247:00 amRNSAstraZeneca increases 2024 dividend by 7%
8th Apr 20247:00 amRNSEnhertu approved in US for HER2+ solid tumours
5th Apr 20247:00 amRNSImfinzi improved OS & PFS in limited-stage SCLC
2nd Apr 20243:00 pmRNSTotal Voting Rights
2nd Apr 20247:05 amRNSVoydeya approved in US
2nd Apr 20247:00 amRNSFDA accepts Dato-DXd BLA for breast cancer
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSAstraZeneca cell & gene therapy deal w/ Cellectis

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.